Genomics: Global Market Analysis, Insights and Forecast, 2019-2026 offers valuable insights into the factors enabling growth in the market. Genomics is most commonly used for the diagnosis of cancer. Recent advancements in personalized medicine and genomics have bought significant transformations in disease management.
The Global Market is expected to rise at an exponential CAGR of 18.7% between 2018 and 2026. In 2018, the market was valued at US$ 15,888.8 Mn and it is anticipated to reach US$ 62,614.6 Mn by 2026.
Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941
Key Industry Developments
- In October 2018, Helix OpCo LLC, announced the launch of DNA Product Studio which will enable development of genomics-based apps and tests.
- In November 2018, Veritas Genetics launched whole genome sequencing products under the flagship myGenome products to provide improved services to its customers.
- In August 2018, 10X Genomics acquired Epinomics, a epigenomics- based startup to strengthen its position and provide new solutions to researchers and pharmaceutical companies.
Veritas Genetics Launched myGenome to Offer Personalized Services to its Customers
General Electric Company, Thermo Fisher Scientific Inc., Oxford Nanopore Technologies, Agilent Technologies, Inc., IntegraGen, QIAGEN, BGI, F. Hoffmann-La Roche Ltd, Danaher, and Illumina, Inc. are some of the leading players in the global genomics market. Among these, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., and Illumina, Inc. are projected to dominate the global market. Strong geographical presence and robust portfolio are factors responsible for their prominent position in the market. Several companies are entering into strategic alliances to better their market position and increase revenue. Bristol Myers Squibb collaborated with Foundation Medicine in March 2017.
This collaboration will help the former company to leverage the latter’s molecular information and genomic profiling solutions. Furthermore, it will help Bristol Myers to identify biomarkers such as Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) in cancer patients. Another company called 10X Genomics acquired an epigenomics-based startup called Epinomics in August 2018. This acquisition will help the company strengthen its market position.
Secondary Data Sources That We Refer To
- Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
- Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
- Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
- Industry journals and paid databases
Secondary Research Is Conducted To Derive The Following Information
- Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
- Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
- Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
- Number of procedures and average price of procedures
- Replacement rate and pricing of capital equipment
- Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
- Market & technological trends, new product developments, product pipeline.